Business context and reporting period
Registrant: MRI Interventions, Inc. The supplied filing is its Form 10-K for the fiscal year ended December 31, 2014; it is not a standalone fourth-quarter report. The filing describes ClearPoint Neuro’s current product name, but the registrant identified here is MRI Interventions, Inc.
The company develops MRI-guided minimally invasive medical-device platforms. ClearPoint, for neurological procedures, was commercially marketed in the U.S. and EU. ClearTrace, for cardiac procedures, remained in development and was not cleared for commercial sale.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Total revenue | $3.60 million | $3.93 million |
| Product revenue | $3.38 million | $2.91 million |
| Operating loss | $5.32 million | $7.47 million |
| Net loss | $4.52 million | $7.09 million |
| Net loss per share, basic and diluted | $0.08 | $0.12 |
| Cash used in operating activities | $7.25 million | $7.78 million |
- Product and other service revenue increased 17% to $3.50 million; disposable-product sales rose 47% to $2.6 million. Total revenue declined about 8% because 2013 included $650,000 of license revenue that ended after March 2013.
- Cost of product revenue was $1.93 million, up 36%. Product revenue less this cost was approximately $1.45 million, or about 43% of product revenue. A roughly $380,000 increase in reserves for obsolete/expired products contributed materially to the cost increase.
- Research and development expense rose 13% to $3.30 million; selling, general and administrative expense rose 14% to $8.04 million.
- 2014 net loss included a $4.34 million gain from selling intellectual property to Boston Scientific, settled by cancellation of related-party notes. The gain was non-cash and improved reported earnings; operating cash use remained $7.25 million.
- Cash and cash equivalents were $9.24 million at year-end, versus $3.52 million in 2013. Current assets were $11.71 million and current liabilities $4.92 million, implying working capital of about $6.79 million. Accumulated deficit was $77.28 million and stockholders’ deficit was $0.10 million.
- Notes payable had $11.01 million of scheduled principal payments: $4.29 million due in 2016, $3.73 million in 2019, and $3.00 million thereafter. The balance-sheet carrying amount of notes payable was approximately $7.69 million, net of discounts; accrued interest was a further $0.88 million. The 2014 secured notes bear 12% interest.
- Cash increased by $5.73 million, primarily due to financing proceeds: $9.38 million net from a December equity-and-warrant placement and $3.50 million net from a March debt placement. The December financing issued 15.8 million shares and warrants; outstanding common shares were 74.84 million at year-end.
Material changes, outlook, and risks
- Management expected 2015 ClearPoint revenue growth from higher use at existing sites and additional installations. It believed year-end cash, together with expected product-sale cash flows, would fund anticipated needs through at least March 31, 2016. These are management estimates, not assurances; the company anticipated continued losses through at least 2015 and may need additional financing.
- ClearTrace development continued under a new exclusive Siemens agreement signed in February 2014. The company did not expect to submit for regulatory clearance or approval within at least the following 12 months and could not estimate completion timing or cost. A U.S. PMA may be required for the ablation catheter.
- In March 2014, Boston Scientific purchased certain MRI-safety intellectual property for $4.34 million by cancelling notes. Amendments eliminated future milestone payments and royalties under the related agreements, while the company retained a license to the transferred IP outside specified fields.
- Key risks include persistent losses and financing needs; uncertain ClearPoint adoption and reimbursement; customer concentration (UCSF and Emory represented 14% and 12% of ClearPoint disposable revenue, respectively); dependence on certain suppliers and a single Irvine assembly site; regulatory and product-liability exposure; and stronger, better-resourced competitors.
- The company planned to close its Memphis office and consolidate operations in Irvine by mid-2015. It expected approximately $450,000 in restructuring costs, largely in the first half of 2015. Management reported effective disclosure controls and internal control over financial reporting at December 31, 2014. No material pending legal proceeding was reported.
Most important facts for investors to verify
- Whether ClearPoint installations and disposable use grow enough to improve recurring revenue and margins, and whether 2015 guidance assumptions are achieved.
- Cash burn, financing availability, and the effect of debt maturities, 12% interest, warrant dilution, and any future capital raising on runway and shareholders.
- The amount and timing of product obsolescence charges and whether inventory can be sold or used without further write-downs.
- ClearTrace development milestones, Siemens agreement economics and exclusivity, regulatory pathway, and funding required before commercialization.
- The full audited financial statements and debt-note terms; the excerpted filing provides no standalone fourth-quarter revenue, profit, cash-flow, or margin figures.